Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Hypomorphic ASGR1 modulates lipid homeostasis via INSIG1-mediated SREBP signaling suppression
Yingying Xu, Jiawang Tao, Xiaorui Yu, Yuhang Wu, Yan Chen, Kai You, Jiaye Zhang, Anteneh Getachew, Tingcai Pan, Yuanqi Zhuang, Fang Yuan, Fan Yang, Xianhua Lin, Yin-xiong Li
Yingying Xu, Jiawang Tao, Xiaorui Yu, Yuhang Wu, Yan Chen, Kai You, Jiaye Zhang, Anteneh Getachew, Tingcai Pan, Yuanqi Zhuang, Fang Yuan, Fan Yang, Xianhua Lin, Yin-xiong Li
View: Text | PDF
Research Article Metabolism

Hypomorphic ASGR1 modulates lipid homeostasis via INSIG1-mediated SREBP signaling suppression

  • Text
  • PDF
Abstract

A population genetic study identified that the asialoglycoprotein receptor 1 (ASGR1) mutation carriers had substantially lower non–HDL-cholesterol (non–HDL-c) levels and reduced risks of cardiovascular diseases. However, the mechanism behind this phenomenon remained unclear. Here, we established Asgr1-knockout mice that represented a plasma lipid profile with significantly lower non–HDL-c and triglyceride (TG) caused by decreased secretion and increased uptake of VLDL/LDL. These 2 phenotypes were linked with the decreased expression of microsomal triglyceride transfer protein and proprotein convertase subtilisin/kexin type 9, 2 key targeted genes of sterol regulatory element–binding proteins (SREBPs). Furthermore, there were fewer nuclear SREBPs (nSREBPs) on account of more SREBPs being trapped in endoplasmic reticulum, which was caused by an increased expression of insulin-induced gene 1 (INSIG1), an anchor of SREBPs. Overexpression and gene knockdown interventions, in different models, were conducted to rescue the ASGR1-deficient phenotypes, and we found that INSIG1 knockdown independently reversed the ASGR1-mutated phenotypes with increased serum total cholesterol, LDL-c, TG, and liver cholesterol content accompanied by restored SREBP signaling. ASGR1 rescue experiments reduced INSIG1 and restored the SREBP network defect as manifested by improved apolipoprotein B secretion and reduced LDL uptake. Our observation demonstrated that increased INSIG1 is a critical factor responsible for ASGR1 deficiency–associated lipid profile changes and nSREBP suppression. This finding of an ASGR1/INSIG1/SREBP axis regulating lipid hemostasis may provide multiple potential targets for lipid-lowering drug development.

Authors

Yingying Xu, Jiawang Tao, Xiaorui Yu, Yuhang Wu, Yan Chen, Kai You, Jiaye Zhang, Anteneh Getachew, Tingcai Pan, Yuanqi Zhuang, Fang Yuan, Fan Yang, Xianhua Lin, Yin-xiong Li

×

Figure 2

VLDL/LDL secretion is reduced accompanied with less microsomal triglyceride transfer protein in ASGR1-deficient mice.

Options: View larger image (or click on image) Download as PowerPoint
VLDL/LDL secretion is reduced accompanied with less microsomal triglycer...
Hepatic lipid secretion assays were conducted on mice with different genotypes. (A) TG and (B) cholesterol content were measured at 0, 1, 2, and 3 hours after i.p. injection with tyloxapol, n = 5. (C) The relative mRNA expression level of secretion-related genes, Apob and microsomal triglyceride transfer protein (Mttp) were analyzed by real-time PCR (RT-PCR) in liver tissues (WT, n = 7; Asgr1+/–, n = 4; Asgr1–/–, n = 7). (D) The corresponding proteins, APOB and MTTP, were analyzed by Western blots in liver tissues. Representative images of the immunoblotting and gray intensity of each band relative to β-actin was shown, n = 3. (E) Secreted APOB content in mouse serum was analyzed by Western blots (WT, n = 3; Asgr1+/–, n = 4; Asgr1–/–, n = 4). Parallel analyses were conducted on HepG2 cell lines. (F) The mRNA expression level of APOB and MTTP was analyzed by RT-PCR (n = 4), and (G) protein content of APOB and MTTP was analyzed by Western blots, n = 4. (H) ELISA comparison of secreted APOB content between WT and ASGR1–/–, n = 4. All data are shown as the means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as compared with the indicated WT by 1-way ANOVA among 3 groups. Statistical significance between 2 groups was assessed with an unpaired, 2-tailed t test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts